Soon-Shiong's cancer drug claims outpace clinical
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Patrick Soon-Shiong's cancer drug proclamations are "mostly fluff, financially self-serving and have led to FDA wrist-slapping," according to the STAT+ analysis
- A wide gap exists between what Soon-Shiong says his cancer drugs can achieve and what they actually demonstrate in real clinical evidence
- Before becoming wealthy and famous, Soon-Shiong treated diabetic patients with pancreas transplants and performed surgery on pancreatic cancer patients
- Soon-Shiong's "Bioshield" mission was inspired by his stated desire to transform pancreatic cancer treatment with novel immunotherapies, per his own treatise
- The STAT+ author acknowledges taking online heat from Soon-Shiong fans who view the billionaire physician as a selfless scientist/entrepreneur trying to rid the world of cancer
Why it matters: Patrick Soon-Shiong has staked his reputation on pancreatic cancer immunotherapy claims that diverge sharply from real clinical evidence — and the FDA has already pushed back. For patients and investors evaluating his pipeline, the gap between promotional narrative and verified trial data is the material question.
Ask SkimNews
